Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Inventors

Kariolis, Mihalis S. • Lenser, Melina • Mahon, Cathal S. • Ngo, Hanh Giai • Rajendra, Yashas • TYAGI, Shrishti • Yuan, Tianao

Assignees

Denali Therapeutics Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12378540-B1

Patent

Publication Date

2025-08-05

Expiration Date


Abstract

Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise an acid alpha-glucosidase (GAA) enzyme-Fc fusion polypeptide. Certain embodiments also provide methods of using such proteins to treat Pompe disease.

Core Innovation

The described ETV:GAA enzyme-replacement proteins comprise a fusion polypeptide in which a first Fc polypeptide is linked to acid alpha-glucosidase (GAA), paired with a second Fc polypeptide engineered to bind the transferrin receptor for blood-brain-barrier transport. The claims define specified sequence alternatives, notably including N-terminal and C-terminal configurations such as a fusion polypeptide comprising SEQ ID NO: 70 paired with a second Fc polypeptide comprising SEQ ID NO: 43 or SEQ ID NO: 44.

In GAA-knockout mouse models of Pompe disease, evaluations report higher brain exposure and reduced glycogen in quadriceps, brain, and heart compared with enzyme-replacement controls such as alglucosidase alfa. In these studies, ETV:GAA fusion proteins reduce glycogen without significant liver glycogen differences, while C-terminal configurations exhibit higher stable-pool titers and purity relative to N-terminal configurations. The patent background section problem is not explicitly described in patent.

Claims Coverage

The three independent claims are claims 1, 14, and 16, which cover three inventive features directed to proteins comprising a GAA-Fc fusion polypeptide and a second Fc polypeptide.

Protein with specified Fc-GAA fusion alternatives

Claim 1 covers a protein comprising a fusion polypeptide in which a first Fc polypeptide is linked to an acid alpha-glucosidase (GAA) enzyme, together with a second Fc polypeptide, wherein the fusion polypeptide comprises SEQ ID NO: 68 paired with SEQ ID NO: 41 or 42, or SEQ ID NO: 70 paired with SEQ ID NO: 43 or 44.

Protein with SEQ ID NO: 70 fusion and SEQ ID NO: 43 second Fc

Claim 14 covers a protein comprising a fusion polypeptide in which a first Fc polypeptide is linked to an acid alpha-glucosidase (GAA) enzyme, wherein the fusion polypeptide comprises SEQ ID NO: 70, and a second Fc polypeptide comprising SEQ ID NO: 43.

Protein with SEQ ID NO: 70 fusion and SEQ ID NO: 44 second Fc

Claim 16 covers a protein comprising a fusion polypeptide in which a first Fc polypeptide is linked to an acid alpha-glucosidase (GAA) enzyme, wherein the fusion polypeptide comprises SEQ ID NO: 70, and a second Fc polypeptide comprising SEQ ID NO: 44.

Together, the independent claims cover the specified Fc-linked GAA protein configurations, including the alternative sequence combinations in claim 1 and the specifically defined combinations in claims 14 and 16.

Stated Advantages

The described proteins exhibit higher brain exposure, reported as approximately 6-10-fold greater brain exposure than alglucosidase alfa and comparator controls in mouse studies, with a dependent claim specifying at least five-fold greater brain uptake of GAA compared with alternatives lacking Fc components or TfR-binding modifications.

Treatment reduces glycogen and glycogen-derived glucose in brain, quadriceps muscle, and heart in GAA-knockout models compared to comparator controls.

The reported C-terminal configurations exhibit higher stable-pool titers and purity relative to N-terminal configurations.

Documented Applications

Treatment of Pompe disease by administering the claimed protein to a patient in need.

Decreasing accumulation of a toxic metabolic product, identified in the claims as glycogen.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.